Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Inavolisib

FDA-approved product (tablet, oral), marketed as Itovebi.

Registered studies
36
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Inavolisib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae41.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

36registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Inavolisib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Inavolisib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

    NCT04589845 · start 2021-01-18

    Registered record
    Registry ID
    NCT04589845
    Conditions
    Solid Tumors
    Interventions
    Entrectinib; Entrectinib; Alectinib; Atezolizumab; Ipatasertib; Trastuzumab emtansine; Inavolisib; Belvarafenib; Pralsetinib; Divarasib; Camonsertib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2021-01-18
    Completion
    2032-09-25
    Enrolment
    920

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumors
    InterventionEntrectinib; Entrectinib; Alectinib; Atezolizumab +7 more
    PhasePhase 2
    Registry statusActive not recruiting

  • A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

    NCT04632992 · start 2021-01-13

    Registered record
    Registry ID
    NCT04632992
    Conditions
    Advanced Unresectable or Metastatic Solid Malignancy
    Interventions
    Entrectinib; Inavolisib; Alectinib; Ipatasertib; Atezolizumab; Trastuzumab Emtansine; Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf; Tucatinib; Investigator's Choice of Chemotherapy; Paclitaxel; Tiragolumab; Pralsetinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-01-13
    Completion
    2024-02-27
    Enrolment
    252

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Unresectable or Metastatic Solid Malignancy
    InterventionEntrectinib; Inavolisib; Alectinib; Ipatasertib +8 more
    PhasePhase 2
    Registry statusCompleted

  • A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

    NCT04449874 · start 2020-07-29

    Registered record
    Registry ID
    NCT04449874
    Conditions
    Non-Small Cell Lung Cancer; Colorectal Cancer; Advanced Solid Tumors
    Interventions
    GDC-6036; Atezolizumab; Cetuximab; Bevacizumab; Erlotinib; GDC-1971; Inavolisib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2020-07-29
    Completion
    2027-12-31
    Enrolment
    498

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer; Colorectal Cancer; Advanced Solid Tumors
    InterventionGDC-6036; Atezolizumab; Cetuximab; Bevacizumab +3 more
    PhasePhase 1
    Registry statusActive not recruiting

  • A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

    NCT04191499 · start 2020-01-29

    Registered record
    Registry ID
    NCT04191499
    Conditions
    Breast Cancer
    Interventions
    Inavolisib; Placebo; Palbociclib; Fulvestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Active not recruiting
    Start
    2020-01-29
    Completion
    2027-11-15
    Enrolment
    325

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionInavolisib; Placebo; Palbociclib; Fulvestrant
    PhasePhase 2 / Phase 3
    Registry statusActive not recruiting

  • A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

    NCT03424005 · start 2018-03-30

    Registered record
    Registry ID
    NCT03424005
    Conditions
    Metastatic Breast Cancer
    Interventions
    Capecitabine; Atezolizumab; Ipatasertib; SGN-LIV1A; Bevacizumab; Chemotherapy (Gemcitabine + Carboplatin or Eribulin); Selicrelumab; Tocilizumab; Nab-Paclitaxel; Sacituzumab Govitecan; Abemaciclib; Fulvestrant; Ribociclib (Dose #1); Inavolisib (Dose #1); Trastuzumab Deruxtecan; Ribociclib (Dose #2); Letrozole; Inavolisib (Dose #2); Empagliflozin; Palbociclib; Metformin; Atirmociclib; Giredestrant
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2018-03-30
    Completion
    2030-09-30
    Enrolment
    1,132

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionCapecitabine; Atezolizumab; Ipatasertib; SGN-LIV1A +19 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

    NCT03006172 · start 2016-12-13

    Registered record
    Registry ID
    NCT03006172
    Conditions
    Breast Cancer; Solid Tumor
    Interventions
    Inavolisib; Fulvestrant; Letrozole; Palbociclib; Metformin; Trastuzumab; Pertuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2016-12-13
    Completion
    2026-12-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Solid Tumor
    InterventionInavolisib; Fulvestrant; Letrozole; Palbociclib +3 more
    PhasePhase 1
    Registry statusActive not recruiting